Symposium at SAGES congress highlights CSR and
multidisciplinary perspective on Stretta for GERD
NORWALK, Connecticut,
April 24, 2017 /PRNewswire/ -- Mederi
Therapeutics has announced that the Society of American
Gastrointestinal and Endoscopic Surgeons (SAGES) recently
issued a Clinical Spotlight Review (CSR) Guideline statement on
Stretta Therapy for GERD. The CSR as well as other new data was
presented during an industry symposium at the recent SAGES 2017
Annual Meeting in Houston, TX.
The new CSR of Endoluminal Treatments for Gastroesophageal
Reflux Disease (GERD), published online, reviews existing data and
provides evidence-based answers to key clinically relevant
questions. Developed by the SAGES Guidelines Committee, the CSR
details outcomes of Stretta as compared to medications or surgery,
along with safety, long-term durability, and procedural learning
curve.
The CSR recommendation states: "Based on existing evidence,
Stretta significantly improves health related quality of life
scores, heartburn scores, incidence of esophagitis, and esophageal
acid exposure in patients with GERD". Regarding Stretta's benefits,
the CSR concluded: "The effectiveness of Stretta diminishes some
over time, but persistent effects have been described for up to 10
years in appropriately selected GERD patients. Stretta is more
effective than PPI, but less so than fundoplication. Stretta is
safe in adults and has a short learning curve. (Level of evidence
+++, Strong recommendation)".
Brian Dunkin, MD, past president
of SAGES, Head of Endoscopic Surgery at the Houston Methodist
Hospital, and Medical Director of the Houston Methodist Institute
for Technology, Innovation & Education (MITIESM) in
Houston, Texas, noted SAGES'
commitment to supporting proven and innovative technologies that
offer safe, effective and durable options for patients. "The SAGES
Guidelines committee recognizes the problem of chronic GERD, noting
that 25-42% of patients with GERD don't achieve adequate response
to an initial 4-8 week treatment with proton pump inhibitors (PPI).
Despite the effectiveness of surgery, it is invasive, requires
hospitalization and has a risk of short and long-term
complications. A "middle therapy" like Stretta, which provides an
option between medications and surgery, is an attractive
alternative to patients, physicians and payers alike."
Mederi hosted a symposium at the SAGES 2017 Annual Meeting that
highlighted the new CSR as well as a recently published Stretta
Meta-Analysis. The symposium featured perspectives on the use of
Stretta to treat GERD by both a Gastroenterologist and a Surgeon.
Speakers, Dr. Nirav Thosani, Chair
of Gastroenterology and Director of Advanced Endocopy at Ertan
Digestive Disease Center at Memorial Hermann Hospital, and Dr.
Samer Mattar, Professor and Chief of
Bariatric Services at Oregon Health Sciences
University, presented on the latest Stretta data and their
view on GERD treatments, describing where Stretta fits in their
practice, and shared positive experiences with Stretta in treating
GERD patients.
ABOUT MEDERI® AND STRETTA®
Mederi manufactures innovative devices that use non-ablative
radiofrequency (RF) energy to treat digestive diseases. Stretta is
an endoscopic, non-surgical treatment that is proven safe and
effective for GERD in 40 studies and is available worldwide.
For more information: stretta-therapy.com, or call
855-855-3639.
Contact: Kara Stephens
407.765.1185
kara@pascalecommunications.com
Photo -
https://mma.prnewswire.com/media/493167/Mederi_Therapeutics_Stretta.jpg